Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    Identification of AAV serotypes for lung gene therapy in human embryonic stem cell derived lung organoids.

    Authors: Helena Meyer-Berg; Lucia Zhou Yang; María Pilar de Lucas; Alberto Zambrano; Stephen C. Hyde; Deborah R. Gill

    doi:10.21203/rs.3.rs-40720/v1 Date: 2020-07-08 Source: ResearchSquare

    Gene therapy is being investigated for a range of serious lung diseases MESHD, such as cystic fibrosis MESHD and emphysema MESHD emphysema HP. Recombinant adeno-associated virus (rAAV) is a well-established, safe, viral-vector for gene delivery with multiple natural and artificial serotypes available displaying alternate cell, tissue and species-specific tropisms. Efficient AAV serotypes for the transduction of the conducting airways have been identified for several species; however, efficient serotypes for human lung parenchyma have not yet been identified. Here, we screened the ability of multiple AAV serotypes to transduce lung bud organoids (LBOs) - a model of human lung parenchyma generated from human embryonic stem cells. Microinjection of LBOs allowed us to model transduction from the luminal surface, similar to dosing via vector inhalation. We identified the natural rAAV2 and rAAV6 serotypes, along with synthetic rAAV6 variants, as having tropism for the human lung parenchyma. Positive staining of LBOs for surfactant proteins B and C confirmed distal lung identity and suggested the suitability of these vectors for the transduction of alveolar type II cells. Our findings establish LBOs as a new model for pulmonary gene therapy and stress the relevance of LBOs as a viral infection MESHD model of the lung parenchyma as relevant in SARS-CoV-2 research.

    Chest CT imaging features of critically ill COVID-19 patients

    Authors: Nan Zhang; Xunhua Xu; Ling-Yan Zhou; Gang Chen; Yu Li; Huiming Yin; Zhonghua Sun

    doi:10.21203/rs.3.rs-18094/v1 Date: 2020-03-19 Source: ResearchSquare

    Objectives To analyze the findings of computed tomography (CT) imaging in critically ill patients diagnosed with coronavirus disease MESHD 2019 (COVID-19).Methods This retrospective study reviewed 60 critically ill patients (43 males TRANS and 17 females TRANS, mean age TRANS 64.4±11.0 years) with COVID-19 pneumonia MESHD pneumonia HP who were admitted to two different clinical centers. Their clinical and medical records were analyzed, and the chest CT images were assessed to determine the involvement of lobes and the distribution of lesions in the lungs between the patients who recovered from the illness and those who died.Results Patients were significantly older in the death MESHD group (10/60, 16.67%) than in the recovery group (50/60, 83.33%) (p=0.044). C-reactive protein (CRP) (67.9±50.5 mg/L) was significantly elevated in the death MESHD group as opposed to the recovery group (p<0.001). The neutrophil-to-lymphocyte ratio (NLR) was higher in the death MESHD group when compared with the recovery group (p=0.030). Involvement of five lung lobes was found in 98% of the patients, with medial or parahilar area involvement observed in all the death MESHD patients. Ground-glass opacities (97%), crazy-paving pattern (92%) and air bronchogram (93%) were the most common radiological findings. Presence of emphysema MESHD emphysema HP was more prevalent in the death MESHD group than in the recovery group (30% vs 2%, p=0.011).Conclusions The degree of lung involvement and lesion distribution with dominance in the medial and parahilar pulmonary areas were more severe in the death MESHD patients than in those who recovered. Patient’s age TRANS, emphysema MESHD emphysema HP, CRP and NLR could be combined with CT to predict the disease MESHD outcomes.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.